Marinus Pharmaceuticals — Investor Presentation (June 2024)
41 slides from Marinus Pharmaceuticals's investor presentation, Jun 17, 2024
Slide 1: Corporate Presentation June 2024
Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation June 2024
Slide 2: Forward-looking statements
©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe
Slide 3: Ganaxolone Development Pipeline
©2024 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 Ganaxolone is a positive allosteric GABA A receptor modulator with a well - defined MOA designed to treat patients suffering from seizure disorders. Ganaxolone is designed to modulate both synaptic and extrasynapt
Slide 4: Commercial Overview
Commercial Overview Not for promotional use
Slide 5: ZTALMY Has the Potential to Significantly Advance Epilepsy Treatment
©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY ® Has the Potential to Significantly Advance Epilepsy Treatment 5 Differentiated MOA addresses unmet need Well - characterized safety profile FDA - approved in CDD Scalable commercial infrastructure supports rapid expansion and adoption Sig
Slide 6: ZTALMY Performance Metrics and Growth Drivers
©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY ® Performance Metrics and Growth Drivers 6 U.S. net product revenue of $7.5M for the first quarter of 2024 >125% growth from Q1 2023 Continued strong new patient enrollments Continued growth of new prescribers driving demand Achieved profit
Slide 7: Expected Significant Near-term Milestones
©2024 Marinus Pharmaceuticals. All Rights Reserved I Program Indication 1H 2024 2H 2024 1H 2025 2H 2025 CDKL5 deficiency disorder Achieved profitability* Tuberous sclerosis complex Completed Phase 3 enrollment Phase 3 TrustTSC readout Potential filing for FDA Approval Potential Launch Developmental
Slide 8: Driving Global Access of ZTALMY (ganaxolone)
©2024 Marinus Pharmaceuticals. All Rights Reserved I Driving Global Access of ZTALMY® ( ganaxolone ) 8 Europe: Collaboration agreement with Orion Corporation for ganaxolone in CDD, TSC, RSE • Up to €90 million of development, commercial, and sales milestones 1 ; tiered royalties in the low double -
Slide 9: Tuberous Sclerosis Complex
Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments.” - Kari Luther Rosbeck, President &
Slide 10: Tuberous Sclerosis Complex (TSC)
©2024 Marinus Pharmaceuticals. All Rights Reserved I Tuberous Sclerosis Complex (TSC) 10 CAUSE • Defect or mutation of TSC1 and/or TSC2 genes INCIDENCE • ~1 in 6,000 live births 1 COMMON SYMPTOMS • Seizures, cognitive impairment, behavioral difficulties, skin/kidney/lung abnormalities, etc. EPILEPSY
Slide 11: TSC Phase 2 Trial Results
©2024 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 11 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 P e r c e n t r e d u c t i o n i n T S C - a s s o c i a t e d s e i z u r e f r e q u e n c y =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 1
Slide 12: Phase 3 Protocol Refinements Informed by Phase 2 Tolerability
©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 Tolerability 12 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy No (n=6) Yes (n=17) 0 5 10 15 20 25 30 Somnolence-related AE P e r c e n t r e d u c t i o
Slide 13: Phase 3 Trial Overview
©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 13 ► Enrollment: ~128 patients, targeting sites in the U.S., Western Europe, Canada, Israel, Australia and China • 90% powered to detect a 25% treatment difference • Statistical significance could be achieved with a treatmen
Slide 14: TrustTSC Baseline Demographics
©2024 Marinus Pharmaceuticals. All Rights Reserved I TrustTSC Baseline Demographics* 14 Age (mean [min - max]) 15 [1 - 50] Gender 52% male 48% female Failed Therapies* (mean) 4.8 Baseline Seizure Rate (median, per 28 days) 50 DB Discontinuation Rate** ~7% 2 discontinuations (<2%) due to somnolence -
Slide 15: Anticipated Commercial Expansion into Tuberous Sclerosis Complex
©2024 Marinus Pharmaceuticals. All Rights Reserved I 15 Influential Advocacy Community Reflects the values and priorities of the TSC community and address es the unique challenges associated with rare genetic epilepsy Significant Market Opportunity TSC can be readily diagnosed, and a substantial por
Slide 16: Unlocking a ~5x Growth Opportunity for ZTALMY in TSC
©2024 Marinus Pharmaceuticals. All Rights Reserved I Unlocking a 4 - 5x Growth O pportunity for ZTALMY ® in TSC 16 1 TSC Alliance; 2 Marinus ZS Opportunity Assessment, 2020 Market Research; 3 Curatolo P - Epilepsy in TSC: Findings from the TOSCA Study; 4 Chu - Shore CJ et al.The natural history of e
Slide 17: Plans to Leverage Existing ZTALMY Infrastructure in TSC
©2024 Marinus Pharmaceuticals. All Rights Reserved I Plans to Leverage Existing ZTALMY ® Infrastructure Expected to Yield Significant Returns in TSC 17 17 COMMERCIAL INFRASTRUCTURE Addition of 12 - 16 RAMs to reach key targets, including 17 TSC COEs MARKET POSITIONING Distinct TSC positioning: First
Slide 18: Significant Growth Potential with Expansion into Larger Indications
©2024 Marinus Pharmaceuticals. All Rights Reserved I Significant Growth Potential with Expansion into Larger Indications 18 ~12k refractory patients in the U.S. ~48k patients in the U.S. ~2k patients in the U.S. CDKL5 Deficiency Disorder Approved in the U.S. and EU Tuberous Sclerosis Complex Potenti
Slide 19: Second Generation Product Development
Second Generation Product Development
Slide 20: Second Generation Ganaxolone Goals
©2024 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone 20 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax - related adverse effects Reduce dosing
Slide 21: Next Steps: Prodrug and Ganaxolone Reformulation
©2024 Marinus Pharmaceuticals. All Rights Reserved I Next Steps: Prodrug and Ganaxolone Reformulation 21 Ganaxolone Prodrug Oral prodrug candidate selected Goals: • Optimize PK parameters for efficacy, tolerability and dosing frequency • Increase absorption (oral), solubility (IV) Preclinical IND -
Slide 22: Status Epilepticus
Status Epilepticus
Slide 23: Status Epilepticus Overview
©2024 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Overview 23 23 Status Epilepticus = Condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to: • abnormally prolonged seizures (after tim
Slide 24: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment
©2024 Marinus Pharmaceuticals. All Rights Reserved I Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment 24 Experimental PK – plasma and brain 1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes 2 EEG bispectral index in healthy volunteers fol
Slide 25: RAISE: Phase 3 Trial in Refractory Status Epilepticus
©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Phase 3 Trial in Refractory Status Epilepticus 25 STUDY POPULATION INTERVENTION CO - PRIMARY ENDPOINTS KEY SECONDARY ENDPOINTS Onset of Action: Proportion of patients with SE cessation within 30 minutes Durability of Effect: Proportion of p
Slide 26: RAISE: Baseline Characteristics
©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Baseline Characteristics 26 *Safety population (unless otherwise noted) A ITT population Baseline Characteristics* Placebo (n = 49) IV Ganaxolone (n = 51) Age (years), median (range) 59 (15 – 90) 60 (16 – 88) Male sex, no. (%) 30 (61.2) 30
Slide 27: RAISE: Co-Primary Endpoints
©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Co - Primary Endpoints 27 Proportion of patients with no progression to IV anesthesia for 36 hours Proportion of patients with SE cessation within 30 minutes without medications for the acute treatment of SE IV Ganaxolone (n = 49) Placebo (
Slide 28: Approach to SRSE
©2024 Marinus Pharmaceuticals. All Rights Reserved I ► SRSE - specific dosing approach • ↓ Cmax but ↑ AUC • 3 - month oral wean • Ganaxolone 833mg/day x48h ➛ 1,050mg/day x 168h • Captisol ® 50gm/day ➛ 63gm/day Approach to SRSE 28 28 29 patients with SRSE treated with IV ganaxolone as of May 2024 14
Slide 29: Super Refractory Status Epilepticus: Ganaxolone Experience to Date
©2024 Marinus Pharmaceuticals. All Rights Reserved I Super Refractory Status Epilepticus: Ganaxolone Experience to Date 29 29 New onset refractory status epilepticus (NORSE) Febrile illness - related epilepsy syndrome (FIRES) Lennox - Gastaut syndrome PCDH - 19 related epilepsy Autoimmune encephalit
Slide 30: i if / y*
i if / y* | “er | . , i a | MARINUS —_ ©
Slide 31: Financial Overview
©2024 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 31 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. T.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann : Michael Higg
Slide 32: Intellectual Property
Intellectual Property
Slide 33: Multiple Layers Of Potential Protection
©2024 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 33 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. U.S.
Slide 34: Appendix
Appendix —— oo ae
Slide 35: A Comprehensive Commercial Strategy to Grow the ZTALMY Brand
©2024 Marinus Pharmaceuticals. All Rights Reserved I A Comprehensive Commercial Strategy to Grow the ZTALMY® Brand 35 Patient identification Activate the caregiver community Focused education to HCPs to establish ZTALMY as the standard of care for CDD seizure management Continuously enhance the pati
Slide 36: Phase 3 CDD Marigold Trial Data and Safety Summary
©2024 Marinus Pharmaceuticals. All Rights Reserved I 36 Ganaxolone Placebo 0 10 20 30 40 M e d i a n P e r c e n t R e d u c t i o n 2 8 - d a y F r e q u e n c y o f M a j o r M o t o r S e i z u r e s 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Difference Patients taking
Slide 37: Average Ganaxolone Levels Correlate with Seizure Reduction
©2024 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction 37 • Logarithms of plasma ganaxolone level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High ganaxolone level groups had a
Slide 38: Phase 3 Open Label Extension Data in CDD
©2024 Marinus Pharmaceuticals. All Rights Reserved I Patients who remained in the clinical trial at 2 years experienced sustained reduction in MMSF 1 ► Following the pivotal trial, 88 out of 101 patients entered an open - label extension study to evaluate the ongoing safety and effi cacy of ZTALMY. 1
Slide 39: Phase 1 Single Ascending Dose (SAD) Study
©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 1 Single Ascending Dose (SAD) Study 39 39 Mean C max (ng/mL) Mean AUC 0 - t (h*ng/mL) 41% 31% 38% 18% 18% 14% Study design Ganaxolone reformulation demonstrated linear kinetics at single doses from 100 - 1200 mg • Single dose PK study in hea
Slide 40: Refractory Status Epilepticus Trial (RSE) Design
©2024 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper Phase 2 Refractory Status Epilepticus Trial (RSE) Design 40 • Diagnosis of convulsive or non - convulsive SE • Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics
Slide 41: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect
©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect 41 Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status - free throu
Marinus Pharmaceuticals — Investor Presentation (June 2024) on 6ix